A

Achilles Therapeutics PLC
NASDAQ:ACHL

Watchlist Manager
Achilles Therapeutics PLC
NASDAQ:ACHL
Watchlist
Price: 1.48 USD 0.68% Market Closed
Market Cap: 60.8m USD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Achilles Therapeutics PLC
NASDAQ:ACHL
60.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
386.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
163.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.6B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.4B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Achilles Therapeutics PLC
Glance View

Market Cap
60.8m USD
Industry
Biotechnology

Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The firm's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.

ACHL Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top